RESEARCH TRIANGLE PARK, N.C. – May 12, 2005 – Quintiles Transnational Corp. today announced it has entered a partnership with Roche for clinical study management services.

The two companies have signed a three-year preferred provider agreement, which will give Roche more flexibility and efficiency in the development of its product pipeline. Analysts regard the Roche pipeline as among the best in the pharmaceutical industry, with medications for diabetes, hepatitis, anemia, rheumatoid arthritis and cancer among those in development.

"This agreement is very important because it may bring a number of new molecular entities to patients sooner," said G. Stephen DeCherney, M.D., MPH, President, Clinical Development Services Americas for Quintiles. "The partnership will enable Quintiles and Roche to make more efficient use of Quintiles' therapeutic expertise and global resources."

"By selecting Quintiles as a partner to manage clinical studies, we are well positioned to successfully handle a substantial increase for new studies in many therapeutic areas," said Dan Zabrowski, Vice President and Global Head of Pharma Development Operations for Roche. "We believe this partnership will greatly improve our flexibility and efficiency, which should bring more medicines to patients more quickly."

Quintiles and Roche have established committees at various levels to assure the success of the partnership and the development programs conducted under the agreement. Each of the three committees has equal representation from Roche and Quintiles.

About Quintiles

Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totaled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.